Actively Recruiting
Cardio-Oncology Intervention to Reduce Heart Risk in Men with Prostate Cancer Undergoing ARPI Therapy
Led by Cedars-Sinai Medical Center · Updated on 2026-10-05
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying men with prostate cancer, especially those with advanced or metastatic disease, who face a high risk of cardiovascular problems. This trial focuses on how androgen receptor pathway inhibitor ARPI therapy, a common prostate cancer treatment, affects heart health. The study aims to test whether early cardio-oncology interventions and personalized heart care can reduce cardiovascular risk during ARPI treatment. It also explores the role of clonal hematopoiesis of indeterminate potential CHIP and metabolic changes in predicting heart risks in these patients. Participants are randomly assigned to either receive a referral to cardio-oncology specialists for personalized heart care or have their primary care doctor or cardiologist notified with recommendations for cardiovascular risk management after starting ARPI therapy. The study compares these two approaches to see which better supports heart health during prostate cancer treatment. The intervention involves guideline-based cardiovascular management to optimize heart risk factors. Throughout the study, participants will be monitored for changes in cardiovascular medications, compliance with treatments like statins, biological heart risk factors, and new heart-related diagnoses. These assessments occur at 3, 6, and 12 months after the intervention. The main outcome is the rate of any cardiovascular medication initiation or change at 3 months. Safety and heart health are closely followed up to one year, with ongoing data collection on heart disease testing and serious cardiac events. Participation may last up to several years until study completion in 2030.
CONDITIONS
Brief Title
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Research Team
C
Clinical Trial Recruitment Navigator
K
Katelyn Atkins, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here